Improved Broth Microdilution Method for Antimicrobial Susceptibility Testing of Francisella Noatunensis Orientalis. Issue 3 (2nd August 2016)

• Record Type: Journal Article
• Authors: Soto, Esteban; Halliday‐Simmonds, Iona; Francis, Stewart; Fraites, Trellor; Martínez‐López, Beatriz; Wiles, Judy; Hawke, John P.; Endris, Richard D.
• Is Part Of: Journal of aquatic animal health. Volume 28:Issue 3(2016)
• Page Start: 199
• Page End: 207
• Publication Date: 2016-08-02
• Subjects: Aquatic animals -- Periodicals; Aquatic animals -- Diseases -- Periodicals; 571.917
• DOI: 10.1080/08997659.2016.1185051
• Languages: English
• ISSNs: 0899-7659

Abstract

Abstract: In this project we optimized a minimal inhibitory concentration testing protocol for Francisella noatunensis orientalis . Thirty‐three F. noatunensis orientalis isolates recovered from different fish species and locations were tested, and Escherichia c o li ATCC 25922 was used as a quality control reference strain. A modified cation‐adjusted Mueller Hinton broth supplemented with 2% IsoVitalex and 0.1% glucose (MMH) was tested at a pH of 6.4 ± 0.1, 7.1 ± 0.1, and 7.3 ± 0.1. Growth curves generated for F. noatunensis orientalis indicated that MMH at a pH of 6.4 ± 0.1 provided optimal growth. There were no significant differences in the growth curves obtained from isolates recovered from different fish species or from fresh or marine water. The pH of 6.4 ± 0.1 in the MMH media interfered with the inhibitory properties of the potentiated sulfonamides (ormetoprim‐sulfadimethoxine and trimethoprim‐sulfamethoxazole) when using the E. coli ATCC reference strain. Minimal inhibitory concentrations of eight antimicrobials (gentamicin, enrofloxacin, ampicillin, oxytetracycline, erythromycin, florfenicol, flumequine, and oxolinic acid) were similar for all F. noatunensis orientalis isolates. The in vitro susceptibility data provided here can provide a baseline for monitoring the development of antimicrobial resistance among F. noatunensis orientalis isolates, as well as provide valuable data in the development of potential therapeutics. Received October 27, 2015; accepted April 13, 2016 Published online August 2, 2016